Su Wei-guo 4

What Happened

• Su Wei‑guo, HUTCHMED’s CEO, Chief Scientific Officer and a director, was allocated a total of 208,004 ordinary shares (132,864 + 75,140) on May 20, 2026 at a purchase price of $0.00. These allocations are reported as "other acquisition" (code J) and reflect awards under the company’s Long Term Incentive Plan (LTIP) after achievement of FY2025 performance conditions.
• This is a compensation award (not an open‑market purchase or sale). The filing lists no cash value (price $0) because the shares were allocated as performance awards rather than bought.

Key Details

• Transaction date(s): May 20, 2026 (reported on Form 4 filed May 21, 2026).
• Share details: 132,864 shares (footnote F1) and 75,140 shares (footnote F2) allocated at $0.00; total = 208,004 shares.
• Vesting/transfer: F1 shares (from Aug 5, 2024 award) expected to vest and transfer in 2027; F2 shares (from June 9, 2025 award) expected to vest and transfer in 2028. Allocated shares are held by the LTIP trustee on the reporting person’s behalf until vesting.
• Shares owned after transaction: not specified in the Form 4 filing.
• Filing timeliness: Reported the next day (May 21, 2026) for the May 20, 2026 transaction — appears timely.
• Codes/notes: Transaction reported with code J (other acquisition/disposition); see footnotes F1 and F2 for award specifics.

Context

• These are performance‑based LTIP allocations (compensation), not open‑market trades. Such awards reflect achievement of company performance goals for FY2025 and are subject to future vesting conditions and trustee holding until transfer.
• Because the shares were allocated at $0, the transaction shows no immediate cash value; it represents potential future equity if vesting and transfer conditions are met.